Lantheus Holdings, Inc.
LNTHHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Lantheus Holdings, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. With a market capitalization of $6.52B, it sits in mid-cap territory. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Market Cap
$6.52B
Beta
-0.06
P/E (TTM)
24.16
P/E (Fwd)
15.65
EPS (TTM)
$4.13
EPS (Fwd)
$6.38
ROE
22.2%
ROA
8.4%
Cash
$593.3M
Total Debt
$625.0M
Free CF
$451.7M
52W Change
78.0%
Annual Financials
Cash vs Debt
Where LNTH stands vs its 150-day and 200-day moving averages
As of the October 7, 2026 close, LNTH finished 5.17% above its 150-day moving average ($95.04) and 13.04% above its 200-day moving average ($88.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LNTH overbought or oversold?
At the October 7, 2026 close, LNTH's RSI(14) was 38.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, LNTH has $593.3M in cash with $625.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $451.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 22.2% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $425.2M (2021) to $1.54B (2025), reflecting a 263% increase over the period.
LNTH's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LNTH.